Drug Database
BL

blood substitute (Volplex / Volplex)

✓ Approved

Sinclair · Cell-based Therapies · Cell-based Therapies

What is blood substitute?

blood substitute is a cell-based therapies developed by Sinclair. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

Brand NamesVolplex, Volplex
CompanySinclair
Drug ClassCell-based Therapies
RouteInjectable (Others), Intravenous (IV)
StatusApproved
Sources: ClinicalTrials.gov, Sinclair

Therapeutic Indications

blood substitute is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Surgical and medical proceduresAdjuvant therapy✓ Approved

Related Research Articles

PubMedJACC. Case reports2026-09-20

Renal Denervation for Uncontrolled Hypertension in a Patient With Mast Cell Activation Syndrome.

Nuvvula Sri S, Mian Maryyam M, Singh Avneet A, Diamond Joseph J

Renal denervation (RDN) is a treatment option for resistant hypertension. We present a 64-year-old woman with medication intolerance secondary to mast cell activation syndrome who presented with uncontrolled hypertension and underwent bilateral RDN. Her systolic and diastolic recordings measured using Dinamap device (GE Healthcare), decreased from 151 ± 7.6 and 75 ± 4.1 mm Hg to 126 ± 4.5 and 66 ± 2.8 mm Hg, respectively, at 3 months after her procedure (both P < 0.05). We show that RDN can be used in patients with severe medication intolerance due to an autoimmune condition. We also highlight the utility of using office-automated testing, which allowed us to likely obtain more accurate multiple blood pressure readings over 15 minutes. This report highlights RDN's efficacy in a patient unable to tolerate pharmacological antihypertensive therapy and highlights the clinical utility of using automated blood pressure readings.

PMID 42763807
Read full article →
PubMedComputational and mathematical methods in medicine2026-09-20

RETRACTION: "Image Segmentation of Retinal Blood Vessels Based on Dual-Attention Multiscale Feature Fusion".

Methods In Medicine Computational And Mathematical CAM

[This retracts the article DOI: 10.1155/2022/8111883.].

PMID 42763464
Read full article →
PubMedInternational journal of genomics2026-09-20

Downregulation of IFNG-AS1 and UCHL1-AS1 in Peripheral Blood Cells of Multiple Sclerosis Patients: IFNG-AS1 as a Candidate Diagnostic Biomarker.

Rajabi Ali A, Gross Jeffrey D JD, Samadi Ali A

Multiple sclerosis (MS) is a neurodegenerative and inflammatory disease affecting gray and white matter in the brain. Due to the highly variable presentation of MS, making a reliable long-term diagnosis based solely on initial clinical findings is extremely challenging. Long noncoding RNAs (lncRNAs) have been shown in recent research to have a role as prospective biomarkers that may offer data to forecast the onset and course of disease. A total of 100 healthy controls and 120 MS patients with 98 relapsing-remitting (RR), 10 primary progressive (PP), and 12 secondary progressive (SP) cases were included in the blood sample collection. Gene expression was assessed with quantitative real-time PCR. The receiver operating characteristic (ROC) curve analysis was employed to evaluate the potential for diagnostic analysis of lncRNA levels. The expressions of IFNG-AS1 and UCHL1-AS1 were found to be significantly decreased (p < 0.0001) in patients compared to the control group. After adjustment for age using ANCOVA, IFNG-AS1 expression remained significantly lower in MS patients than in healthy controls (p < 0.0001). IFNG-AS1 may be considered a potential biomarker for MS diagnosis (AUC = 0.838). IFNG-AS1 demonstrates promising diagnostic potential for MS, whereas UCHL1-AS1 shows only modest discriminatory value. However, these findings are preliminary and require further validation with functional studies to confirm clinical utility.

PMID 42763619
Read full article →
PubMedUltrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology2026-09-20

Imaging in gynecological disease (32): clinical and ultrasound characteristics of early abdominal ectopic pregnancy.

Berg L L, De Braud L V LV, Bean E E, Lomheim M M et al.

To compare clinical and sonographic characteristics of first-trimester abdominal ectopic pregnancy (AEP) with those of tubal ectopic pregnancy (TEP), and to define ultrasound-based diagnostic criteria for AEP. This was a retrospective case-control study comparing cases of AEP diagnosed at four centers with controls diagnosed with TEP, between May 2008 and May 2025. AEP was defined as a pregnancy implanted within the peritoneal cavity outside the uterus, ovaries and Fallopian tubes. We compared demographics, clinical and ultrasound findings and clinical outcomes between the groups. We identified the key ultrasound features of first-trimester AEP and used these to develop refined diagnostic criteria. During the study period, 19 cases of AEP were identified and compared to 57 controls with TEP. The groups were matched for age, parity and gestational age at presentation. Compared with TEP, AEP was more likely to occur in pregnancies conceived via in-vitro fertilization (6/19 (32%) vs 5/57 (9%); odds ratio (OR) 4.80 (95% CI, 1.27-18.21); P = 0.02; adjusted OR (aOR), 5.02 (95% CI, 1.24-20.25); P = 0.02) and patients with AEP were less likely to present with vaginal bleeding (5/18 (28%) vs 40/57 (70%); OR, 0.16 (95% CI, 0.05-0.53); P = 0.003; aOR, 0.17 (95% CI, 0.05-0.64); P = 0.009). With respect to clinical outcomes, patients with AEP were more likely to have significant blood loss (≥ 500 ml) at surgery (4/16 (25%) vs 1/36 (3%); OR, 11.67 (95% CI, 1.18-114.90); P = 0.04) and require blood transfusion (4/19 (21%) vs 0/56 (0%); P = 0.003). Four diagnostic ultrasound criteria for AEP were identified: (1) the presence of a gestational sac or trophoblast separate from the uterus and ovaries; (2) the absence of a hypoechogenic tissue layer surrounding the pregnancy; (3) a negative 'sliding organs' sign; and (4) trophoblastic blood flow arising from the peritoneum detected on color Doppler examination. Assisted conception is a risk factor for a pregnancy implanting into the peritoneal cavity. Early ultrasound diagnosis of AEP is important to reduce the risk of major intra-abdominal bleeding, which is significantly higher in AEP compared with TEP. © 2026 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.

PMID 42763435
Read full article →
PubMedCureus2026-09-20

A Randomized Study to Evaluate the Efficacy of Tele-Follow-Up Compared With Standard Follow-Up in Patients Undergoing Coronary Angioplasty and Stenting: A Six-Month Study at a Tertiary Care Hospital.

Mavani Kishan K, Kumar Barun B, Kant Ravi R, Krishnan Vijay V et al.

Background Coronary artery disease (CAD) remains a major cause of morbidity and mortality worldwide. Despite advances in percutaneous coronary intervention (PCI), recurrent cardiovascular events remain common due to gaps in secondary prevention and long-term follow-up. Telemedicine offers a potential solution by improving access to care, patient engagement, and risk-factor monitoring. Methods This single-center, open-label randomized controlled trial included 106 patients undergoing PCI at All India Institute of Medical Sciences (AIIMS), Rishikesh, India, who were randomized 1:1 to structured tele-follow-up (WhatsApp, SMS, and audio/video consultations) or standard outpatient follow-up. Of these, 100 participants completed follow-up and were included in the available-case analysis. The primary outcome was major adverse cardiovascular events (MACEs) assessed at prespecified one-, three-, and six-month follow-up assessments. Secondary outcomes included medication adherence, lipid control, blood pressure control, glycemic control, lifestyle modification, and hospital readmissions. Results The mean age was 55.5 ± 9.2 years, and 88% were male. MACE rates were comparable between groups throughout follow-up (p > 0.05). Tele-follow-up achieved significantly lower low-density lipoprotein cholesterol (LDL-C) levels at one month (69.72 vs. 87.08 mg/dL, p = 0.003) and at six months (53.90 vs. 63.58 mg/dL, p = 0.014). Blood pressure control was generally comparable between groups, with an isolated lower diastolic blood pressure in the tele-follow-up group at one month that was not sustained at subsequent follow-up. Medication adherence was ≥94% in both groups throughout follow-up. No significant differences were observed in HbA1c, systolic blood pressure, bleeding events, stent failure, or mortality. Conclusions Structured tele-follow-up after PCI was feasible, with observed short-term clinical outcomes comparable to standard follow-up. It was associated with better lipid control, while blood pressure control was broadly similar between the groups. Tele-follow-up may therefore be a practical and scalable follow-up strategy after PCI, particularly in resource-limited settings. Larger multicenter studies with longer follow-up are needed to confirm its impact on clinical outcomes.

PMID 42763699
Read full article →
PubMedSpinal cord2026-09-20

Blood flow restricted exercise with and without transcutaneous spinal cord stimulation via telehealth in persons with tetraplegia. A protocol for randomized clinical trial.

Gorgey Ashraf S AS, Rehman Muhammad U MU, Wasim Momal M, Khalil Refka E RE et al.

A single site randomized clinical trial; Richmond, VA, USA. To determine the effect of 16 weeks of home-based blood flow restriction-enhanced neuromuscular electrical stimulation (BES) and non-invasive transcutaneous spinal cord stimulation (TSS) with mass practiced (MP) training on cervical neuroplasticity and upper extremity function in individuals with tetraplegia. The program is supported by a telehealth-based approach designed to improve adherence. Forty-four adults (18-70 years) with incomplete cervical SCI (AIS B-D; injury level C8 or above) will be randomized to TSS + BES + MP or sham TSS + BES + MP for 30 weeks. All participants, accompanied by a caregiver, will complete a 4-week education and training phase (2 weeks on-site, 2 weeks via telehealth), followed by 16 weeks of telehealth-supervised home training. Baseline assessments will occur before training (BL1) and after the education phase (Phase 1, BL2). Post-intervention (P1) testing will follow 16 weeks of home-based training (Phase 2), with an additional follow-up (Fw) after an 8-week washout period to evaluate any carry-over effects (Phase 3). The first 15 months will serve as a feasibility phase without randomization; data from these participants will be included within the TSS + BES + MP group. Randomization thereafter will be conducted using a computer-generated sequence. Home-based TSS application for upper extremity function is a feasible and safe strategy in persons with tetraplegia. The proposal is likely to ensure long-term compliance and adherence as well as to reduce the barriers associated with exercise interventions in persons with tetraplegia. National Institute on Disability, Independent Living, and Rehabilitation Research [NIDILRR]. NCT05423600.

PMID 42763327
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about blood substitute